SynthesisFrontiers in immunology2023

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.

Muhammad Khan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.